DiaMedica Therapeutics Inc. (DMAC) stock
DMACNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.79−0.54 (-5.79%)
Close on Nov 13, 2026Market cap $474.01MP/E –Yield –
DiaMedica Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
DiaMedica Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$41.81M. For fiscal 2025 it was -$34.40M. The highest annual figure on record is -$4.52M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$34.40M | – |
| FY2024 | Dec 31, 2024 | -$26.68M | – |
| FY2023 | Dec 31, 2023 | -$21.27M | – |
| FY2022 | Dec 31, 2022 | -$14.00M | – |
| FY2021 | Dec 31, 2021 | -$13.65M | – |
| FY2020 | Dec 31, 2020 | -$12.70M | – |
| FY2019 | Dec 31, 2019 | -$11.59M | – |
| FY2018 | Dec 31, 2018 | -$6.76M | – |
| FY2017 | Dec 31, 2017 | -$4.52M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$11.62M | – |
| Q2 FY2026 | Jun 30, 2026 | -$10.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.48M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.21M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.03M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.01M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.14M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.42M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.88M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.64M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.85M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.16M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.74M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.97M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.13M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.36M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.54M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.25M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.42M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.37M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.62M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.71M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.40M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.77M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.66M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.74M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.42M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.12M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.49M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.85M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.31M | – |
See a number that looks wrong?